TargetBeta
TEK
TEK receptor tyrosine kinase · also TIE2, TIE-2, VMCM1, CD202b · CD molecules
1 program in company-led studies act on TEK, from 1 company: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 404 running | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Hepatocellular, 1 program
- Colorectal Neoplasms, 1 program
- Neoplasms, 1 program
- Pancreatic Neoplasms, 1 program
- Squamous Cell Carcinoma of Head and Neck, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Sep 30, 2027regorafenib · Bayer · phase 4 · NCT02955940
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.